FINWIRES · TerminalLIVE
FINWIRES

$IOVA

6 stories mentioning IOVAUpdated 9d ago

Every FINWIRES story that references IOVA, newest first.

What's the latest news on IOVA?

Wire

Cellectis Shares Fall After Realigning Focus to Become in Vivo Gene Editing Company

Cellectis (CLLS) shares were down nearly 40% in Monday trading after the company said it will realign its focus to become an in vivo gene editing company developing long-lasting treatments for chronic diseases.This transformation follows the "promising" preclinical proof-of-concept for its lead candidate programs -- HEAL-101 for severe hypertriglyceridemia and HEAL-201 for severe hypercholesterolemia, the company said.Cellectis will also exit development of lasme-cel and eti-cel, while seeking partnership opportunities to maximize their value, it said.Cellectis will shift resources to focus on its in vivo gene editing pipeline and support its existing cell therapy partnerships with AstraZeneca (AZN), Allogene (ALLO), Servier and Iovance (IOVA), extending its cash runway into H2 of 2028, the company said.Price: $1.87, Change: $-1.23, Percent Change: -39.68%

$ALLO$AZN$CLLS$IOVA
Wire

Iovance's Growth Outlook Clouded as Amtagvi Faces Competition Hurdles, UBS Says

Iovance Biotherapeutics' (IOVA) pace of growth remains uncertain as Amtagvi, its cell therapy for advanced melanoma, faces competitive pressure and slow onboarding at authorized treatment centers, UBS Securities said Wednesday in a report.Amtagvi revenue of $91 million in Q2 topped the $80 million estimate by UBS. Management is expected to lift its 2026 total-revenue guidance of $350 million to $370 million before Q3 results, though emerging melanoma therapies could add to competitive pressure on Amtagvi as the market evolves, the report said.UBS forecasts Q3 Amtagvi revenue of $96 million and 2026 total revenue of $405 million. It expects additional treatment-center activations to support growth and said onboarding times remain lengthy, often six months or more, due to logistical and treatment-process requirements.UBS raised its price target on Iovance stock to $7 from $4 and maintained its neutral rating.Price: $8.70, Change: $+0.71, Percent Change: +8.82%

$IOVA
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.2%.In corporate news, Entrada Therapeutics (TRDA) shares tumbled 57% after its drug for children with Duchenne muscular dystrophy fell short of analyst expectations in an early-to-mid stage trial, Reuters reported Thursday.Iovance Biotherapeutics (IOVA) shares fell past 13% after the company's Q1 loss narrowed less than expected and revenue missed estimates.Harmony Biosciences (HRMY) shares dropped 5.5% after the company's Q1 earnings and revenue fell short of analysts' estimates.Catalyst Pharmaceuticals (CPRX) shares rose 2.1% after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse.

$CPRX$HRMY$IOVA$TRDA
Sectors

Sector Update: Health Care Stocks Decline in Afternoon Trading

Health care stocks declined Thursday afternoon with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.6%.In corporate news, Iovance Biotherapeutics (IOVA) shares fell past 13% after the company's Q1 loss narrowed less than expected and revenue missed estimates.Harmony Biosciences (HRMY) shares dropped 5% after the company's Q1 earnings and revenue fell short of analysts' estimates.Catalyst Pharmaceuticals (CPRX) shares rose 2.2% after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse.

$CPRX$HRMY$IOVA
Sectors

Sector Update: Health Care

Health care stocks declined Thursday afternoon with the NYSE Health Care Index shedding 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.9%.In corporate news, Iovance Biotherapeutics (IOVA) shares fell 14% after the company's Q1 loss narrowed less than expected and revenue missed estimates.

$IOVA
Wire

Iovance Biotherapeutics Shares Drop After Q1 Results Miss

Iovance Biotherapeutics (IOVA) shares dropped over 11% in Thursday trading after the company reported lower-than-expected Q1 results.The company reported a Q1 net loss of $0.19 per diluted share, narrowing from a loss of $0.36 a year earlier.Analysts polled by FactSet expected a loss of $0.15.Revenue for the quarter ended March 31 was $71.4 million, up from $49.3 million a year earlier.Analysts expected revenue of $77.8 million.The company said it expects its cash position to fund operations well into 2028.Iovance said it expects total product revenue of $86 million to $88 million for Q2, and $350 million to $370 million for 2026.Price: $3.62, Change: $-0.47, Percent Change: -11.49%

$IOVA

Track with the FINWIRES app suite

FolioX
FolioX
Track IOVA in your portfolio
WheelAI
WheelAI
Analyze IOVA options with the wheel strategy
StockInsider
StockInsider
See market sentiment on IOVA